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Background: No case report has yet shown that sunitinib therapy for the postoperative recurrence of renal cancer
in a native kidney after renal transplantation can achieve complete response (CR).
Case presentation: A tumor was detected in the right native kidney of a 35-year-old Japanese male 10 years after
renal transplantation. A tumor thrombus that reached the atrium was detected, which suggested cT3cN0M0.
Because of the risk of perioperative complications, preoperative therapy with sunitinib was selected and 8 courses
were administered. The size of the primary tumor was reduced by 33%, while that of the tumor thrombus was
decreased by 39.5%.
Right nephrectomy and removal of the tumor thrombus were then performed. Contrast-enhanced computed
tomography (CT) four months after surgery suggested local relapse. Sunitinib was administered for 9 months, which
led to complete response (CR).
Conclusions: This study presented the case of sunitinib therapy for renal cancer in the native kidney after renal
transplantation. The therapeutic efficacy and safety for such cases should be discussed.
Keywords: Complete response, Native kidney, Neoadjuvant therapy, Presurgical therapy, Renal cell cancer, Renal
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The usefulness of preoperative drug therapy for im-
proving the safety of surgery or preserving kidney
function in patients with progressive renal cancer has
been reported with the introduction of molecule-
targeting drugs, [1], but this has yet to be confirmed.
Sunitinib, a multitargeting tyrosine kinase inhibitor
(TKI), has been established as a first-line therapy for
metastatic clear cell renal cell carcinoma (cc RCC) [2]
and was administered in the present case.
Complete response (CR) has been reported previously in
patients treated with sunitinib or sorafenib, but was rare
at less than 1% [3,4]. No case report has yet showed that
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achieve CR.Case presentation
A 35-year-old Japanese male presented with abdominal
pain.
Computed tomography (CT) revealed a right renal
tumor with a venous to arterial thrombus (Figure 1). No
remarkable invasion in the peripheral organs or metastasis
was observed. The stage of the tumor was determined to
be cT3N0M0. The level of the tumor embolism was evalu-
ated as IV based on Novic’s classification. The eastern co-
operative oncology group- performance status (ECOG-PS)
was evaluated as 1. The patient had a medical history of
renal transplantation at 26 years of age and immunoglon-
blin A (IgA) nephropathy, and was being treated with the
immunosuppressants tacrolimus and prednisolone.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Computed tomography scan before preoperative sunitinib therapy. The level of tumor thrombus was evaluated as IV according to
Novic’s classification. The red circle indicates the tumor thrombus.
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formed promptly or drug therapy should initially be
conducted, the risk of perioperative complications was
explained to the patient and his family. Preoperative
drug therapy with sunitinib was subsequently selected.
The risk according to the Memorial Sloan Kettering
Cancer Center (MSKCC) scale was regarded as inter-
mediate (hemoglobin and time from the diagnosis to
treatment).
Eight courses of sunitinib therapy were administered.
Because the patient had previously undergone renal
transplantation, the initial dose of sunitinib adminis-
tered was 25 mg. This dose was gradually increased
while monitoring the patient for adverse events: 1st to
2nd courses, 25 mg; 3rd to 4th courses, 37.5 mg; 5th to
7th courses, 50 mg; and 8th course, 37.5 mg. Edema was
exacerbated during the 2 weeks of discontinuation;
therefore, the discontinuation period was established
as 7 to 10 days from the 4th course. The relative dose
intensity was 79% in all courses.
After the 1st course had been completed, CT revealed
that the sizes of the primary focus and tumor thrombus
were decreased by 13% and 17%, respectively (Response
evaluation criteria in solid tumors [RECIST] ver 1.1).
Sunitinib therapy was conducted for 10 months.Although no changes were observed in the level of the
tumor thrombus (IV), the size of the primary tumor de-
creased by 33%, while that of the tumor thrombus was
reduced by 39.5% (Figure 2). Edema (G2), fever (G1),
general malaise (G2), and an increase in creatinine level
(3.71 mg/dl, G2) were observed as adverse events.
Surgery was performed using the following proce-
dures: an L-shaped dermal incision, liver mobilization,
securing the right ureter/renal vein, and ligation of the
renal artery.
Peripheral inferior vena cava (IVC) blood flow was
blocked by cardiopulmonary bypass. The IVC to the
right atrial region was incised to extirpate the right atrial
tumor. Adhesion was noted between the tumor embolus
and vascular wall. The right kidney and tumor embolus
were extirpated as a mass. The IVC wall was partially
and simultaneously resected.
The operation time was 17 hours and 43 minutes. The
volume of intraoperative blood lost was 9,807 cc, while
that of blood loss in the presence of a Cell Saver® was
23,578 cc. Regarding blood transfusions, 130 units of red
blood cells (RBC), 80 units of fresh frozen plasma (FFP),
and 20 units of platelets (Plt) were required.
Histopathologically, clear cell carcinoma with a sar-
comatoid component (less than 10%) (pT3c, G2 = G1 >
Figure 2 Computed tomography scan after 10 months of preoperative sunitinib therapy. The level of tumor thrombus was evaluated as IV
according to Novic’s classification; there were no changes from before sunitinib therapy. However, the size of the primary tumor was reduced by
33%, and that of the tumor thrombus decreased by 39.5%. The red circle indicates the primary tumor and thrombus.
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cer cell nest with vitrification and necrosis was ob-
served in the tumor embolus.
Right subclavian arterial hemorrhage (post operative
day (POD) 14, Clavien Grade IIIa), abdominal wound
infection (POD 35, Grade IIIb), and central venous cath-
eter infection (POD 89, Grade II) occurred as perioperative
complications. The patient was discharged on the 113th
postoperative day.Postoperative course
CT revealed a recurrent tumor (measuring 20 mm) in
the right retroperitoneal floor 1 month after surgery,
which had increased to 45 mm at 4 months after sur-
gery (Figure 3a). A partial response was achieved after
3 months of therapy, as shown by a 73% reduction in
the size of the tumor. CT showed a CR after the admin-
istration of sunitinib for 9 months (Figure 3b). An add-
itional course was subsequently administered, and the
treatment was completed after 11 months. No relapse
or metastasis as observed during the 2-year follow-up
following completion of the administration of sunitinib(interval from the start of treatment: 3 years), and CR
was maintained.
Discussions
The preoperative administration of drugs was not com-
monly performed previously. However, the introduc-
tion of molecule-targeting drugs for metastatic renal
cancer has markedly changed the treatment algorithm
[5]. TKI was shown to reduce the size of tumors, which
suggested the efficacy of preoperative administration.
Schrader et al. [6] reviewed 33 patients who were ad-
ministered treatments preoperatively, and showed a re-
duction in the size of the tumor embolus in most
cases, which facilitated surgery. However, preoperative
administration was not beneficial for all patients. A
retrospective, large-scale study was performed to
examine the vena cava tumor thrombus-minimizing ef-
fects of molecule-targeting drugs [7]. As a prospective
study, a phase II study involving 30 patients preopera-
tively administered sunitinib was performed. The me-
dian rate of the decrease observed in the primary
tumor (renal clear cell carcinoma) size was 28% (abso-
lute reduction: 1.7 cm). Of these patients, the primary
ab
Figure 3 Postoperative computed tomography scan. A
complete response was achieved after the 7th course of sunitinib
therapy for local relapse. Four months after surgery, a computed
tomography scan showed that the tumor had increased to 45 mm
(a). The administration of sunitinib was started. After 9 months of
therapy, a complete response was achieved (b). The red circle
indicates the local recurrent tumor.
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preoperative sunitinib therapy was achieved in 13
patients (45%) [8].
TKIs such as sunitinib and sorafenib may represent
treatment options because they are not contraindicated
in patients with a transplant under immunosuppressive
therapy [9]. Tumor reductions of approximately 40%
and 20% have been achieved previously with sunitinib
and sorafenib, respectively [10-12]. Therefore, we chose
sunitinib as the therapy option.
In the present case, no changes were observed in the
level of the tumor thrombus after preoperative adminis-
tration; however, its size was reduced by 33.9%.
Relapse was detected after surgery. However, drug
therapy rapidly reduced the size of the tumor, leading to
CR. The proportion of patients with CR achieved by ad-
ministration of a TKI such as sunitinib is reportedly 1%
or less [4]. Another study showed that CR was achieved
by the administration of TKIs (sequential sunitinib-sorafenib) for local relapse after nephrectomy [13]. Be-
cause cancer is a mass of diverse clones, the degree of vas-
cular endothelial growth factor (VEGF) dependency may
vary. In the present case, differences were detected in CT
findings between the recurrent and primary tumors; the
former remained unchanged, while changes were observed
in the latter. Therefore, the recurrent tumor may have
been a group of highly VEGF-dependent cells with rela-
tively similar characteristics to the primary tumor. There-
fore, CR may have been associated with TKI treatment.
The appropriateness of discontinuing the administra-
tion of sunitinib after achieving CR has not yet been
fully discussed [14]. In this study, the drug continued to
be administered for a short term after CR was achieved,
and was only discontinued after it had been confirmed
that CR was maintained, and, in the absence of relapse,
had not resumed.
To the best of our knowledge, the safe use and effect-
iveness of sorafenib, but not sunitinib has already been
described for immunosuppressed renal transplant recipi-
ents with advanced RCC [15].
Surgery for RCC with a tumor thrombus in the IVC,
especially Levels III to IV, is challenging. Previous case
reports, including the present case, have not suggested
the usefulness of preoperative administration.
Conclusions
A case of pre- and postsurgical sunitinib treatment for a
renal transplant recipient is reported herein. The neoad-
juvant sunitinib treatment did not decrease the tumor
thrombus with arterial extension. On the other hand, su-
nitinib therapy led to CR for local relapse after surgery.
We described only one case and did not have enough
data and reviewed literatures. The therapeutic efficacy
and safety as in such cases should be studied.Consent
Written informed consent was obtained from the patient
for publication of this Case Report and any accompany-
ing images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
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